TY - JOUR
T1 - Biomarkers of Oxidative Stress in Systemic Lupus Erythematosus Patients with Active Nephritis
AU - Dutch LN Studies
AU - Liu, Lu
AU - de Leeuw, Karina
AU - Arends, Suzanne
AU - Doornbos-van der Meer, Berber
AU - Bulthuis, Marian L C
AU - van Goor, Harry
AU - Westra, Johanna
PY - 2023/8/17
Y1 - 2023/8/17
N2 - Oxidative stress plays an important role in systemic lupus erythematosus (SLE) and especially in lupus nephritis (LN). The aim of this study was to compare redox-related biomarkers between patients with active LN, quiescent SLE (Q-SLE) and healthy controls (HC) and to explore their association with clinical characteristics such as disease activity in patients. We investigated levels of plasma free thiols (R-SH, sulfhydryl groups), levels of soluble receptor for advanced glycation end products (sRAGE) and levels of malondialdehyde (MDA) in SLE patients with active LN ( n = 23), patients with quiescent SLE ( n = 47) and HC ( n = 23). Data of LN patients who previously participated in Dutch lupus nephritis studies and longitudinal samples up to 36 months were analyzed. Thiol levels were lower in active LN at baseline and Q-SLE patients compared to HC. In generalized estimating equation (GEE) modelling, free thiol levels were negatively correlated with the Systemic Lupus Erythematosus Disease Activity Index (SLEDAI) over time ( p < 0.001). sRAGE and MDA were positively correlated with the SLEDAI over time ( p = 0.035 and p = 0.016, respectively). These results indicate that oxidative stress levels in LN patients are increased compared to HC and associated with SLE disease activity. Therefore, interventional therapy to restore redox homeostasis may be useful as an adjunctive therapy in the treatment of oxidative damage in SLE.
AB - Oxidative stress plays an important role in systemic lupus erythematosus (SLE) and especially in lupus nephritis (LN). The aim of this study was to compare redox-related biomarkers between patients with active LN, quiescent SLE (Q-SLE) and healthy controls (HC) and to explore their association with clinical characteristics such as disease activity in patients. We investigated levels of plasma free thiols (R-SH, sulfhydryl groups), levels of soluble receptor for advanced glycation end products (sRAGE) and levels of malondialdehyde (MDA) in SLE patients with active LN ( n = 23), patients with quiescent SLE ( n = 47) and HC ( n = 23). Data of LN patients who previously participated in Dutch lupus nephritis studies and longitudinal samples up to 36 months were analyzed. Thiol levels were lower in active LN at baseline and Q-SLE patients compared to HC. In generalized estimating equation (GEE) modelling, free thiol levels were negatively correlated with the Systemic Lupus Erythematosus Disease Activity Index (SLEDAI) over time ( p < 0.001). sRAGE and MDA were positively correlated with the SLEDAI over time ( p = 0.035 and p = 0.016, respectively). These results indicate that oxidative stress levels in LN patients are increased compared to HC and associated with SLE disease activity. Therefore, interventional therapy to restore redox homeostasis may be useful as an adjunctive therapy in the treatment of oxidative damage in SLE.
U2 - 10.3390/antiox12081627
DO - 10.3390/antiox12081627
M3 - Article
C2 - 37627622
SN - 2076-3921
VL - 12
JO - Antioxidants
JF - Antioxidants
IS - 8
M1 - 1627
ER -